close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

6.820 +0.170 (+2.56%)
Streaming Delayed Price Updated: 12:58 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NextCure, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
From NextCure
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Kartoon Studios (NYSE: TOON) Enters Catalyst-Rich Growth Phase
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts
Via AB Newswire
Topics Artificial Intelligence
News headline image
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
From NextCure
Via GlobeNewswire
News headline image
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 
From NextCure
Via GlobeNewswire
News headline image
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
From NextCure
Via GlobeNewswire
News headline image
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
From NextCure
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.